The metastatic spread of tumor cells is the most lethal aspect of cancer and often occurs via the lymphatic vasculature. Both experimental tumor models and human clinicopathologic data indicate that growth of lymphatic vessels (lymphangiogenesis) near solid tumors is often associated with lymph node metastasis. Changes in the adhesive properties of lymphatic endothelium near tumors may also facilitate metastatic spread via the lymphatics. Lymphangiogenic growth factors have been identified that promote formation of tumor lymphatics and metastatic spread of tumor cells to lymph nodes. These include the secreted glycoproteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D, which act via their cognate receptor tyrosine kinase VEGF receptor-3 (VEGFR-3) located on lymphatic endothelial cells. Other signaling molecules that have been reported to promote lymphangiogenesis and/or lymphatic metastasis in cancer include VEGF-A, platelet-derived growth factor-BB, and hepatocyte growth factor. However, the quantitative contribution of these proteins to tumor lymphangiogenesis and lymphatic metastasis in different tumor types requires further investigation. In addition, chemokines are thought to play a role in attracting tumor cells and lymphatic vessels to each other. Moreover, it has recently been shown that lymphangiogenic growth factors secreted from a primary tumor can induce lymphangiogenesis in nearby lymph nodes, even before arrival of tumor cells, which may facilitate further metastasis. This article provides an overview of the molecular mechanisms that control lymphatic metastasis and discusses potential therapeutic approaches for inhibiting this process in human cancer.
Introduction
The spread of tumor cells to lymph nodes is an early and common event in human cancer, and the lymphatic vasculature is therefore considered an important route of metastatic spread. Lymph node metastasis can be an early event in metastatic disease and is useful for the staging of cancer in the clinic. 1 The presence of tumor foci in lymph nodes is considered an adverse prognostic factor in almost all carcinomas, in what otherwise might have been considered localized disease. Further, the detection of tumor cells in lymphatic vessels and regional lymph nodes can lead to treatment of regional lymph nodes by surgery and radiation therapy. [2] [3] [4] Importantly, inhibition of lymph node metastasis was associated with reduced distant organ metastasis in rodent models of cancer, suggesting there may be a pathway facilitating distant organ metastasis via the lymph nodes.
Lymphatic metastasis was previously thought to be a passive process by which detached tumor cells enter lymph nodes via pre-existing lymphatic vessels in the vicinity of a primary tumor 7 -entry to the lymphatics would be facilitated by the thin walls and incomplete basement membrane of lymphatics [8] [9] [10] which would not provide a significant barrier to entry of tumor cells. However, studies in animal models of cancer, employing lymphangiogenic growth factors and histochemical markers that discriminate between blood vessels and lymphatics, indicated that lymphangiogenesis is associated with, and may facilitate, metastasis (for review see Saharinen et al. 11 and Stacker et al. 12 ). Furthermore, clinicopathologic studies indicated that lymphangiogenesis can occur near or in human tumors (for review of methodology for quantitating lymphangiogenesis in human tumors see Van der Auwera et al. 13 ), and this may correlate with metastasis to lymph nodes in some tumors, such as cutaneous melanoma, 14 inflammatory breast carcinoma, 15 non-small cell lung cancer, 16 muscle-invasive transitional cell carcinoma of the bladder, 17 and head and neck cancer. 18 The location of lymphatic vessels relative to a primary tumor may be a determinant of metastatic spread as studies in animal models have indicated that intratumoral lymphatics are nonfunctional, but peritumoral lymphatics FIGURE 1. Schematic representation of potential routes of metastasis via the lymphatic vasculature (yellow), blood vessels (red) and lymph nodes. Lymphangiogenesis in the vicinity of the primary tumor (denoted by lymphatics around the tumor) and metastatic spread of tumor cells to lymph nodes can be promoted by lymphangiogenic growth factors, such as VEGF-C and VEGF-D, and chemokines may contribute by attracting tumor cells toward lymphatic vessels. These factors may be secreted directly by the tumor cells or by stromal cells, such as macrophages/monocytes. Larger lymphatic vessels may undergo an increase in their diameter, which can also encourage the spread of tumor cells. The presence of tumor cells can also induce lymphangiogenesis in the lymph nodes (denoted by extra lymphatics in the nodes) and potentially other changes to the morphology and function of various vessel types in the lymph node, providing a site for rearrangement of the vessel structures and abnormal connections between the vascular and lymphatic networks. These changes to vessels can occur before (due to the release of soluble factors) or after arrival of tumor cells at the node, and this may facilitate further spread to other distant lymph nodes or major organs, such as the lungs, liver, brain, or bone. Tumor cells could spread from lymph nodes to distant organs via blood vessels associated with the nodes or by entering the venous system via the major lymphatic ducts (e.g., the thoracic duct) and then spreading via blood vessels. Alternatively, tumor cells could spread directly from the primary tumor to distant organs via blood vessels, a process that may be facilitated by tumor angiogenesis stimulated by such growth factors as VEGF-A, VEGF-C, and VEGF-D. (Adapted from Tobler and Detmar. 136 ) are capable of draining fluid and cells from a tumor so they may be more important for the metastatic process. 19 Despite the studies of animal tumor models indicating that tumor lymphangiogenesis was associated with metastasis, metastatic spread to lymph nodes in some animal models occurred in the absence of tumor lymphangiogenesis, presumably via pre-existing lymphatic vessels. 20 This suggests that the importance of lymphangiogenesis in metastasis may vary, depending on parameters, such as the tumor type, and the position of the primary tumor relative to the lymphatic network.
An alternative site at which lymphangiogenesis may promote metastatic spread is within the sentinel lymph nodes (FIG. 1) . It has been observed in animal tumor models that this can begin even before tumor cells arrive in the nodes, presumably promoted by lymphangiogenic growth factors derived from the primary tumor, and it has been proposed that this process may facilitate further metastatic spread to distant organs. 6, [21] [22] [23] In a clinical setting, lymphangiogenesis has been detected in lymph node metastases in breast cancer. 24 The experimental and clinicopathologic studies of tumor lymphangiogenesis suggest that the molecular signaling pathways controlling this process may be targets for therapeutics designed to restrict the metastatic spread of cancer. 25, 26 Given that in many cases the primary tumor is surgically excised from the patient, an antimetastatic therapeutic approach could be useful for restricting the spread of tumor cells from remnants of primary tumor that were not successfully removed during surgery. Alternatively, such an approach may be beneficial for inhibiting spread of tumor cells from inoperable primary tumors or from pre-existing cancer metastases in lymph nodes or distant organs. 27, 28 Lymphangiogenic Signaling in the Primary Tumor
The VEGF-C/VEGF-D/VEGFR-3 Signaling Axis
The most extensively studied molecular system that signals for tumor lymphangiogenesis and is associated with lymphatic spread from primary cancers is the VEGF-C/VEGF-D/VEGFR-3 signaling axis. The secreted glycoproteins VEGF-C or VEGF-D activate VEGFR-3, 29,30 a cell surface receptor tyrosine kinase on lymphatic endothelium, 31 leading to growth of lymphatic vessels. [32] [33] [34] [35] [36] Activation of VEGFR-3 is sufficient to protect cultured lymphatic endothelial cells from apoptosis and to induce proliferation and migration of these cells-some of these signals are transmitted via activation of the p42/p44 MAPK signaling cascade in a protein kinase C-dependent fashion and via induction of Akt phosphorylation, signaling systems that are associated with cell growth and survival. 37 Further aspects of VEGFR-3 signaling may be complicated by the fact that VEGFR-3 can form heterodimers with the structurally related receptor VEGFR-2, 38 which can also be localized on lymphatic endothelial cells. 39 Expression of VEGF-C or VEGF-D by tumor cells in xenograft or transgenic animal models of cancer led to an increase in the abundance of lymphatic vessels at the periphery of and sometimes inside the primary tumor, promoted spread of tumor cells to lymph nodes and, in some models, facilitated distant organ metastasis. 34, [40] [41] [42] [43] [44] [45] [46] Inhibition of this signaling pathway, using a soluble form of VEGFR-3 to sequester VEGF-C and VEGF-D, reduced both tumor lymphangiogenesis and lymphatic metastasis in some animal models of cancer. [47] [48] [49] Similar results were observed with a neutralizing VEGF-D monoclonal antibody (mAb) 34 or a neutralizing VEGFR-3 mAb. 50, 51 Despite the abundance of data from animal tumor models showing that the VEGF-C/VEGF-D/VEGFR-3 axis promotes tumor lymphangiogenesis and metastatic spread, the question arises as to whether these proteins exert similar effects in human cancer. Importantly, the expression of VEGF-C, VEGF-D, and VEGFR-3 correlates with lymphatic metastasis in some prevalent forms of human cancer, a topic which has been reviewed on multiple occasions in the past. 12, 52, 53 For example, VEGF-C levels in primary tumors correlate with lymph node metastasis in prostate, 54 gastric, 55 thyroid, 56 colorectal, 57 esophageal, 58 and lung carcinomas. 59 In addition, VEGF-C was reported to be a potential prognostic factor in cervical and ovarian carcinomas. 60, 61 VEGF-D was reported to be an independent prognostic marker for disease-free and overall survival in colorectal carcinoma that correlates with lymphatic involvement. 62 Furthermore, it has been reported that the presence of both VEGF-D and VEGFR-3 in endometrial carcinoma may predict myometrial invasion and lymph node metastasis and may prospectively identify patients at increased risk for poor outcome, 63 and that VEGF-D and VEGFR-3 are independent prognostic markers in gastric adenocarcinoma. 64 In addition, VEGF-D was observed to be expressed in glioblastoma multiforme 65 and was found to be an independent predictor of poor outcome in epithelial ovarian carcinoma, 66 and expression of VEGFR-3 by lymphatic endothelial cells was reported to be associated with lymph node metastasis in prostate cancer. 67 Although not all studies of VEGF-C or VEGF-D expression in human cancer support a role for these molecules in tumor lymphangiogenesis and metastatic spread (see, for example, the report from Gisterek and colleagues 68 ), it is fair to conclude that the majority of the many studies conducted on this topic support this hypothesis.
Of importance, VEGF-C and VEGF-D can be proteolytically processed [69] [70] [71] by enzymes, such as plasmin 72 and proprotein convertases 73, 74 -this process increases the affinity of these growth factors for both VEGFR-3 and VEGFR-2. Processing of these ligands appears to be particularly important for the capacity to activate VEGFR-2, 69,70,74 a receptor that is also activated by VEGF-A and signals for tumor angiogenesis. 75, 76 VEGF-C and VEGF-D can promote angiogenesis in different biological settings, [77] [78] [79] [80] [81] [82] including cancer, 34, 42, 46 and the proteolytically processed forms of these growth factors may contribute to signaling for tumor angiogenesis by binding VEGFR-2. 83 Clinical studies demonstrated that a neutralizing mAb to VEGF-A (known as Avastin TM or bevacizumab), which prevents binding to VEGFR-2, is beneficial for patients with metastatic colorectal cancer (for review see Ferrara et al. 84 ). It is possible that human tumors could "escape" therapies targeting VEGF-A by employing other angiogenic signaling molecules, 85 such as the alternative VEGFR-2 ligands VEGF-C or VEGF-D. Moreover, VEGFR-3 can be expressed on blood vessels in cancer 86, 87 and may contribute to tumor angiogenesis and solid tumor growth: This hypothesis is supported by the finding that treatment of tumor xenograft models with neutralizing VEGFR-3 mAbs restricted both angiogenesis and tumor growth. 88 Therefore, therapeutics that target VEGF-C and VEGF-D may augment the anti-angiogenic effects of targeting VEGF-A, and thereby further restrict solid tumor growth, in addition to restricting tumor lymphangiogenesis and metastasis via the lymphatic vasculature.
VEGF-A/VEGFR-2
VEGF-A is an angiogenic protein that can be expressed in hypoxic regions of tumors 89, 90 and that activates VEGFR-1 and VEGFR-2 on the endothelial cells lining blood vessels (for review, see Ferrara et al. 91 ). VEGFR-2 can also be expressed on the endothelium of lymphatic vessels, 39 suggesting that its activation by VEGF-A could contribute to lymphangiogenic signaling. Expression of VEGF-A in a chemically induced skin carcinogenesis model 21 and in a tumor xenograft model utilizing fibrosarcoma cells 92 led to enhanced lymphangiogenesis and lymph node metastasis. Furthermore, treatment of an orthotopic breast carcinoma model with a neutralizing VEGF-A antibody reduced both lymphatic vessel density and lymph node metastasis. 93 However, VEGF-A did not promote lymphangiogenesis or lymph node metastasis in some animal tumor models 34, 94 and the variables determining whether or not it exerts these effects in cancer are not well understood. These variables could include (a) the recruitment by VEGF-A of monocytes or other cell types expressing VEGF-C and/or VEGF-D to the tumor; (b) the isoform(s) of VEGF-A being expressed by tumor cells or tumor stroma; and (c) the absolute levels of VEGFR-2 on the endothelium of lymphatics near the tumor.
Other Secreted Growth Factors
A range of other growth factors has been reported to exhibit lymphangiogenic activity and promote lymph node metastasis in cancer. For example, expression of platelet-derived growth factor-BB in murine fibrosarcoma cells induced tumor lymphangiogenesis in syngeneic mice, causing formation of intratumoral lymphatics that led to enhanced metastasis to lymph nodes. 95 Hepatocyte growth factor (HGF) promoted lymphangiogenesis in vivo when overexpressed in transgenic mice or delivered subcutaneously 96 and appeared to promote peritumoral lymphangiogenesis in a transgenic model of mammary tumorigenesis. 97 However, the role of HGF in lymph node metastasis is yet to be established, although a correlation has been reported between expression or mutation of its receptor, known as HGF-R or MET/c-met, and the metastatic spread of cancer. 98 The angiopoietins (Angs) are ligands for the endothelial cell surface receptor Tie2 (for review, see Thurston 99 ): Ang-1 activates Tie2 and positively regulates remodeling of blood vessels, 100 whereas Ang-2 promotes blood vessel regression by blocking Tie2 activation. 101 Loss of Ang-2 in mice causes defects in patterning and function of the lymphatic vasculature that can be rescued by Ang-1, suggesting a role for these proteins in lymphangiogenesis, 102 which has been supported by studies in other animal models. 103, 104 The VEGF-C/VEGF-D/VEGFR-3 system is thought to be involved in Ang-1-mediated lymphangiogenic signaling. 103 However, there have not yet been any reports showing that Ang-1 or Ang-2 promote tumor lymphangiogenesis or lymphatic metastasis in animal models. The insulin-like growth factors (IGFs), IGF-1 and IGF-2, exhibited lymphangiogenic activity in mouse cornea, 105 are expressed in many human tumors and have been associated with malignant progression and poor prognosis. 106 Of interest, IGF-1 receptor promoted expression of VEGF-C and lymph node metastasis in a Lewis lung carcinoma model, suggesting that it could act as a positive regulator of VEGF-C in cancer and thereby promote lymphatic metastasis. 107 However, analyses of IGF effects on tumor lymphatics and lymph node metastasis in animal models have not been reported.
It will be important to assess the role of these growth factors in lymphatic metastasis by (a) specifically targeting them, or their receptors, in a range of animal tumor models that exhibit metastatic spread via the lymphatics; (b) determining whether their effects in cancer are mediated directly or indirectly via the VEGF-C/VEGF-D/VEGFR-3 signaling axis; and (c) establishing whether their expression in a range of prevalent forms of human cancer correlates with lymph node and/or distant metastasis.
Lymph Node Lymphangiogenesis in Cancer
It has been observed that lymphangiogenesis in cancer is not restricted to regions within or immediately adjacent to a primary tumor, but can also occur in the sentinel lymph nodes (FIG. 1) . For example, lymphangiogenesis was reported in lymph nodes that contained tumor cells expressing VEGF-D in the setting of a mouse xenograft model, 34 and Hirakawa and colleagues employed a chemically induced skin carcinogenesis model overexpressing VEGF-A to demonstrate that VEGF-A promoted lymphangiogenesis in metastasis-containing lymph nodes. 21 Intriguingly, the primary tumors expressing VEGF-A in this model induced sentinel lymph node lymphangiogenesis even before metastasizing tumor cells had arrived at these nodes. In fact, it has been known for many years that regional lymph nodes draining tumors can be enlarged without evidence of metastasis, a condition known as tumor-reactive lymphadenopathy (for review, see Ioachim 108 ). VEGF-C also promoted expansion of the lymphatic networks in sentinel lymph nodes prior to the onset of metastasis in a chemically induced skin carcinogenesis model. 6 Similarly, a study of B16 melanoma cells implanted in syngeneic mice demonstrated that tumor-draining lymph nodes featured greatly increased lymphatic sinuses and that lymphangiogenesis began in these nodes before the arrival of melanoma cells, indicating that primary tumors induce these alterations at a distance. 22 Further, lymph flow was greatly increased through tumor-draining relative to non-draining lymph nodes. This study indicated that lymph node lymphangiogenesis can be dependent on the accumulation of B lymphocytes in the draining lymph nodes. In a another study utilizing animal models it was observed that before the establishment of metastasis in the sentinel lymph node, there is reorganization of the lymphatic channels, such that the lymph node became a "lymph vessel/sinus enriched organ." 23 Lymphangiogenesis has also been identified in the lymph nodes of mice developing lymphomas. 109 Human lymph nodes infiltrated with metastatic melanoma or breast cancer cells also exhibited lymphatic vessel growth, indicating that lymph node lymphangiogenesis can be a feature of human cancer. 24, 110 It has been proposed that the lymphangiogenesis in lymph nodes containing tumor cells might facilitate further metastatic spread throughout the lymphatic system. Interestingly, in the chemically induced skin carcinogenesis model, mice with metastasis-containing sentinel lymph nodes that expressed VEGF-C were more likely to have metastasis to additional organs including distal lymph nodes and lungs, and no metastases were observed in distant organs in the absence of lymph node metastases. 6 These findings suggest an important role for both lymph node lymphangiogenesis and tumor lymphangiogenic growth factors in cancer metastasis beyond the sentinel lymph nodes. Further, the occurrence of lymphangiogenesis in sentinel lymph nodes prior to arrival of tumor cells indicates that signals derived from the primary tumor are transported to the draining lymph nodes, where they induce localized lymphatic vessel growth. 21 This is a new variant of the "seed and soil" hypothesis by which organ-specific characteristics are responsible for the preferential patterns of metastasis exhibited by distinct tumor types.
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In this scenario, primary tumors might modify the "soil" in the lymph node to make it better suited for supporting further metastatic spread. The analysis of more murine and human cancers is required to establish whether lymphangiogenesis in tumor-draining lymph nodes and increased lymph flow are features of cancer in general, and if they might allow identification of those lesions more likely to metastasize. The assessment of the propensity for metastasis could be based on monitoring the abundance of lymphatics in or adjacent to a primary tumor or sentinel lymph node, or analyzing expression of lymphangiogenic growth factors and their cognate receptors at these sites.
Chemokines and Lymphatic Metastasis
Chemokines are a family of more than 40 small chemoattractant cytokines that bind to G proteincoupled receptors expressed on target cells, allowing these cells to follow chemokine concentration gradients into selected tissues. 112, 113 Chemokines and their receptors are essential for leukocyte trafficking and have also been implicated in cancer metastasis to specific organs. For example, transduction of the B16 murine melanoma cell line with a retroviral vector encoding the chemokine receptor CCR7 resulted in greatly enhanced spread of tumor cells to draining lymph nodes which could be blocked by neutralizing antibodies to CCL21, a chemokine that binds CCR7 and is constitutively produced by lymphatic endothelial cells in the skin. 114 This study suggests that chemokines can attract tumor cells to lymphatic vessels in the vicinity of a tumor to promote lymph node metastasis, which has also been observed in another animal model of melanoma. 115 Furthermore, overexpression of the chemokine receptor CXCR4 in oral squamous cell carcinoma promoted lymph node metastasis in an orthotopic mouse model, 116 and neutralizing the interaction of the chemokine CXCL12 with CXCR4 expressed on tumor cells significantly impaired metastasis of breast cancer cells to regional lymph nodes and lung in a mouse model of tumor development. 117 A role for the chemokine receptor CXCR3 in metastasis of colon cancer and melanoma cells to lymph nodes was also demonstrated in animal models. 118, 119 The involvement of chemokines in lymphatic metastasis is also supported by clinicopathologic data: For example, it has been reported that expression of CCR7 is associated with lymph node metastasis of gastric carcinoma, 120 colorectal carcinoma 121 and breast cancer, 122 and that expression of CXCR4 significantly correlated with lymphatic metastasis as well as distant dissemination in hepatocellular carcinoma 123 and is associated with lymph node metastasis in oral squamous cell carcinoma 124 and with lymph node status in breast cancer. 125 In summary, studies over the past 10 years suggest that while production of lymphangiogenic growth factors, such as VEGF-C or VEGF-D, by tumor cells or the tumor stroma attract growth of lymphatic vessels expressing VEGFR-3 toward the primary tumor, chemokines secreted by lymphatic vessels or lymph nodes may attract the movement of tumor cells expressing cognate chemokine receptors toward these structures. 115 These signal transduction systems could thereby constitute a two-way signaling mechanism, promoting lymph node and possibly distant organ metastases, which offers attractive therapeutic targets for novel drugs designed to restrict the metastatic spread of cancer.
Therapeutic Opportunities
The VEGF-C/VEGF-D/VEGFR-3 axis is the best validated signaling system for promoting lymphangiogenesis associated with solid tumors and the metastatic spread of tumor cells to lymph nodes. A role for VEGF-A is also supported by studies in multiple animal models of cancer. Given that these growth factors can promote lymphangiogenesis in the setting of solid tumors, they are also likely candidates for driving lymph node lymphangiogenesis that appears to promote metastatic spread to sentinel lymph nodes and perhaps to more distant sites. In fact, VEGF-C, VEGF-D, and VEGF-A have already been shown to promote lymph node lymphangiogenesis, at least in animal tumor models overexpressing these growth factors. 6, 21, 34 Hence it would be attractive to target VEGF-C, VEGF-D, and VEGF-A signaling in order to block lymphangiogenesis, both in the vicinity of the primary tumor and in draining lymph nodes, and thereby restrict the metastatic spread of cancer. This may have the attraction of restricting metastasis via the blood vessels by decreased tumor angiogenesis, as well as restricting metastasis via the lymphatic vasculature. VEGF-A can be specifically targeted with Avastin, which could be combined with reagents targeting VEGF-C and VEGF-D, such as a soluble version of VEGFR-3, 5, [47] [48] [49] or neutralizing mAbs to these growth factors. 34, 126 Alternatively, Avastin could be combined with a neutralizing mAb to VEGFR-3, 88,127 although this would not block the effects of VEGF-C and VEGF-D mediated by VEGFR-2. (It would be attractive to block the signaling via VEGFR-2 to restrict tumor angiogenesis and solid tumor growth.) Another approach would be to make use of small-molecule tyrosine kinase inhibitors that block the enzymatic activity of both VEGFR-2 and VEGFR-3, such as sorafenib 128 or sunitinib (also known as SU-11248) 129, 130 and thus inhibit the contribution of both receptors to tumor angiogenesis and lymphangiogenesis. However, such small-molecule inhibitors usually inhibit a range of kinases in the cell so side-effects, particularly when these agents are combined with chemotherapy, must be carefully examined. 131 A range of studies utilizing a soluble form of VEGFR-3, 132 a neutralizing VEGFR-3 mAb, 127, 132 or mice in which the Vegf-d gene has been inactivated 133 suggest that specifically targeting the VEGF-C/VEGF-D/VEGFR-3 signaling axis in cancer patients is unlikely to be problematic in terms of perturbing the function of the adult lymphatic system.
Similar strategies could be employed to target the chemokine signaling systems in cancer. Neutralizing antibodies to specific chemokines or their cognate receptors have been employed in animal models to explore the significance of these molecules in metastasis, 114, 115, 117 and may also be useful in a clinical setting. Further, small-molecule orally active inhibitors of chemokine receptors could also be employed-such an inhibitor for CCR1, designated MLN3897, has been characterized and is already under evaluation in Phase II clinical trials for rheumatoid arthritis and multiple sclerosis. 134 Further, the bicyclam AMD3100 is an inhibitor of CXCR4 which inhibited growth of tumors in an animal model. 135 
Concluding Remarks
Our knowledge of the molecular mechanisms controlling lymphatic metastasis has advanced greatly over the past 10 years, and this progress has provided opportunities for therapeutic interventions designed to restrict the metastatic spread of cancer. The VEGF-C/VEGF-D/VEGFR-3 lymphangiogenic signaling axis is an attractive target for this purpose, but an approach whereby signaling of VEGF-C and VEGF-D via VEGFR-2 is also blocked might provide the extra benefit of restricting tumor angiogenesis and solid tumor growth. The chemokine system is another potential target for restricting cancer metastasis and could conceivably be targeted simultaneously with the lymphangiogenic signaling systems to achieve the most complete inhibition of lymphatic metastasis. A range of potential therapeutic agents has been generated to each of these signaling systems, some of which are already approved for use in the clinic, whereas others await clinical trials to establish their utility as cancer therapeutics. Testing these novel agents in carefully designed clinical trials to assess effects on metastatic disease is now a high priority.
